jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Cancer Profile (Women)

Cancer

6 parameters

image

Report in 8Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Multiplex tumor marker test.

₹2,399₹4,599

48% OFF

Parameters

  • List of Tests
    • Alpha Feto Protein (AFP)
    • Beta HCG
    • CA 19.9
    • CA125
    • Ca15.3
    • Carcino Embryonic Antigen (CEA)

Cancer Profile (Women)

  • Why is it done?
    • This comprehensive test package measures multiple tumor markers simultaneously to screen for and monitor various cancers commonly affecting women, including ovarian, breast, colorectal, pancreatic, and liver cancers
    • Alpha Feto Protein (AFP): Screens for hepatocellular carcinoma (liver cancer), germ cell tumors, and pregnancy-related conditions; used in high-risk populations with cirrhosis or chronic hepatitis
    • Beta HCG: Primarily detects gestational trophoblastic disease, molar pregnancies, and germ cell tumors; elevated levels outside pregnancy warrant investigation for malignancy
    • CA 19.9: Detects pancreatic, colorectal, gastric, and biliary tract cancers; serves as a biomarker for disease progression and treatment response monitoring
    • CA125: Predominantly used for ovarian cancer screening, diagnosis, and monitoring; also elevated in endometrial, fallopian tube, and peritoneal cancers
    • CA 15.3: Specifically useful for breast cancer monitoring and detection; elevated in advanced breast cancer and certain gynecological malignancies
    • Carcinoembryonic Antigen (CEA): Screens for colorectal, breast, gastric, and lung cancers; useful in post-operative monitoring for recurrence
    • Recommended for initial cancer screening in symptomatic women, baseline assessment before cancer treatment initiation, regular monitoring in cancer survivors, and surveillance in high-risk individuals with family history
    • These tests work synergistically to provide multi-site cancer surveillance; abnormalities in multiple markers increase specificity and clinical significance
  • Normal Range
    • Alpha Feto Protein (AFP): Less than 10 ng/mL (nanograms/milliliter); values >20 ng/mL are considered abnormal and warrant further investigation
    • Beta HCG (Human Chorionic Gonadotropin): Less than 5 mIU/mL (milli-International Units/milliliter) in non-pregnant women; <1 mIU/mL is considered truly negative; any detectable level in non-pregnant women requires investigation
    • CA 19.9: Less than 37 U/mL (Units/milliliter); levels 37-100 U/mL warrant clinical correlation; levels >100 U/mL are highly suggestive of malignancy
    • CA125: Less than 35 U/mL (Units/milliliter) in postmenopausal women; <30 U/mL in premenopausal women; borderline elevations (35-100 U/mL) may have benign causes
    • CA 15.3: Less than 30 U/mL (Units/milliliter); 30-65 U/mL considered borderline; >65 U/mL significantly elevated and warrants clinical investigation
    • Carcinoembryonic Antigen (CEA): <2.5 ng/mL in non-smokers; <5 ng/mL in smokers; values >10 ng/mL are concerning for malignancy
    • Normal results indicate no detectable tumor markers; however, absence of elevation does not exclude malignancy, as some early-stage cancers may not elevate these markers
    • Reference ranges may vary slightly between laboratories; consult specific laboratory reference values for accurate interpretation
  • Interpretation
    • Alpha Feto Protein (AFP): Elevated levels (>20 ng/mL) suggest hepatocellular carcinoma, hepatic cirrhosis, chronic hepatitis B or C, germ cell tumors, or benign liver disease; serial measurements tracking trend is more clinically significant than single values
    • Beta HCG: Any detectable level in non-pregnant women is abnormal; elevated Beta HCG suggests gestational trophoblastic disease, choriocarcinoma, dysgerminoma, or other germ cell malignancies; progressive elevation over serial tests indicates active disease
    • CA 19.9: Levels >100 U/mL highly suggestive of pancreatic or gastric cancer; moderate elevations (37-100 U/mL) warrant imaging studies and clinical correlation; benign causes include pancreatitis, cirrhosis, and diabetes; false positives occur in 5-10% of healthy individuals
    • CA125: Elevations >100 U/mL suggest ovarian or peritoneal cancer; moderate elevations may indicate benign conditions including endometriosis, menstruation, fibroids, cirrhosis, or recent abdominal surgery; serial monitoring more valuable than isolated measurements; can normalize with treatment response
    • CA 15.3: Elevations particularly concerning for advanced breast cancer or bone metastases; levels >65 U/mL warrant mammography and ultrasound imaging; benign elevations associated with benign breast disease, inflammation, or liver disease
    • Carcinoembryonic Antigen (CEA): Elevated CEA (>10 ng/mL) suggests colorectal, gastric, or breast cancer; mild elevations associated with smoking, inflammatory bowel disease, cirrhosis, and benign polyps; smokers have naturally higher baseline levels; progressive elevation over time more significant than isolated elevation
    • Combined interpretation: Multiple markers simultaneously elevated increases specificity for malignancy; isolated marker elevation requires correlation with imaging, clinical presentation, and risk factors; trending of serial values over time provides better diagnostic utility than single measurements
    • Important note: Tumor markers are not definitive diagnostic tests; abnormal results require correlation with imaging studies, tissue diagnosis, clinical examination, and complete medical history before confirming malignancy
    • False negatives: Early-stage cancers may not elevate markers; normal results do not exclude malignancy in symptomatic patients
  • Associated Organs
    • Alpha Feto Protein (AFP): Associated with liver, germ cells (ovaries and testes), and pregnancy-related conditions; evaluates hepatic function and malignant potential; abnormal AFP may indicate hepatocellular carcinoma, cirrhosis, hepatitis, or embryonal cancers
    • Beta HCG: Associated with uterus, ovaries, and placental tissue; detects gestational trophoblastic diseases, choriocarcinoma, dysgerminoma, and teratomas; elevated levels indicate abnormal pregnancy or germ cell malignancy with risk of metastatic disease
    • CA 19.9: Associated with pancreas, colon, stomach, bile ducts, and liver; produced by malignant cells in these organs; elevated CA 19.9 indicates potential pancreatic cancer (70-80% of cases), colorectal cancer, or gastric malignancy
    • CA125: Primarily associated with ovaries, peritoneum, endometrium, and fallopian tubes; elevated levels suggest ovarian cancer (80% of advanced cases), endometrial cancer, peritoneal cancer, or cirrhosis; used for ovarian cancer surveillance and treatment monitoring
    • CA 15.3: Specifically associated with breast epithelium and breast cancer detection; elevated in 50-90% of metastatic breast cancer patients; also produced by ovaries, endometrium, and gastrointestinal tract; useful for monitoring treatment response and detecting recurrence
    • Carcinoembryonic Antigen (CEA): Associated with colon, rectum, stomach, pancreas, breast, and liver; elevated in colorectal cancer (60-70% of cases), gastric cancer, pancreatic cancer, and breast cancer; assists in monitoring for recurrence in colorectal cancer patients
    • Complications of abnormal results include progression to metastatic disease, organ dysfunction, reduced treatment efficacy, and need for aggressive therapeutic intervention
    • Organ dysfunction risks: Elevated markers may indicate significant tumor burden affecting organ function and potentially compromising liver, kidney, gastrointestinal, and reproductive system health
  • Follow-up Tests
    • Alpha Feto Protein (AFP) Elevation Follow-up: Abdominal ultrasound or CT scan for liver imaging; liver function tests (bilirubin, albumin, AST, ALT); hepatitis B and C serology; alpha-feto protein ultrasound-guided biopsy if imaging findings warrant; repeat AFP in 4-6 weeks to assess trend
    • Beta HCG Elevation Follow-up: Pelvic ultrasound to exclude pregnancy or gestational trophoblastic disease; chest X-ray and brain MRI if germ cell tumor suspected; repeat Beta HCG weekly until undetectable; CT pelvis/abdomen for staging if malignancy confirmed; refer to oncology for management
    • CA 19.9 Elevation Follow-up: CT abdomen and pelvis with contrast for pancreatic and colonic imaging; endoscopic ultrasound (EUS) for pancreatic lesions; colonoscopy if colonic cancer suspected; endoscopy for gastric evaluation; repeat CA 19.9 in 2-4 weeks; CA 125 and CEA to assess multi-site involvement
    • CA125 Elevation Follow-up: Pelvic ultrasound (transvaginal recommended) for ovarian evaluation; abdominal CT with contrast for peritoneal assessment; consider MRI for better soft tissue characterization; repeat CA125 in 2 weeks; gynecologic oncology referral if significantly elevated; consider diagnostic laparoscopy if imaging inconclusive
    • CA 15.3 Elevation Follow-up: Bilateral mammography and breast ultrasound for lesion detection; breast MRI for comprehensive breast tissue evaluation; bone scan or PET-CT for metastatic disease screening; repeat CA 15.3 in 2-4 weeks; oncology referral for treatment planning
    • Carcinoembryonic Antigen (CEA) Elevation Follow-up: Colonoscopy if CEA elevated and colorectal cancer suspected; upper endoscopy for gastric evaluation; CT chest/abdomen/pelvis for metastatic disease assessment; repeat CEA in 4-6 weeks; smoking cessation counseling; consider PET-CT for staging
    • Comprehensive follow-up approach: Complete blood count, metabolic panel, and liver function tests; tissue diagnosis via biopsy when imaging shows abnormality; genetic testing (BRCA1/BRCA2 for ovarian/breast concern, Lynch syndrome screening for colorectal)
    • Cancer monitoring frequency: For diagnosed cancer, repeat marker panel every 3 months during active treatment, then every 6 months for 2-3 years; more frequent monitoring (monthly) if marker levels rising; annual screening in cancer survivors with normal baseline markers
    • Additional imaging modalities: PET-CT for metabolic assessment and distant metastases; MRI for soft tissue characterization; endoscopic procedures (colonoscopy, esophagogastroduodenoscopy, endoscopic ultrasound)
  • Fasting Required?
    • Fasting is NOT required for this test package
    • All individual markers (AFP, Beta HCG, CA 19.9, CA125, CA 15.3, and CEA) can be reliably measured in non-fasting state
    • Patient may consume normal meals and beverages before blood draw; no food or fluid restrictions necessary
    • Medications: No medications need to be held before testing; continue all routine medications as prescribed by physician
    • Timing considerations: Schedule blood draw in morning when possible for consistency with previous baseline measurements; time of day may affect some marker levels slightly
    • Patient preparation: Arrive 10-15 minutes early for check-in; remain calm to minimize stress-related hormone changes; ensure adequate hydration as this facilitates blood draw
    • Menstrual cycle consideration: For CA125, if possible, draw blood in postmenstrual phase (days 9-13 of cycle) to minimize physiologically elevated levels; document menstrual status in test requisition
    • Recent events to note: Inform phlebotomist of recent surgery, biopsies, trauma, or illness within past 2 weeks as these may artificially elevate tumor markers
    • Specimen requirements: Single blood draw for all six markers; typically 5-10 mL serum sample collected in standard SST (serum separator tube); sample processed and analyzed within 24 hours for optimal accuracy

How our test process works!

customers
customers